Oppenheimer increased its price target for Trevi Therapeutics Inc. (NASDAQ:TRVI) to $23 from $20, while maintaining an ...

Oppenheimer maintained its Outperform rating on Trevi Therapeutics, Inc. (NASDAQ:TRVI) shares and lifted the price target ...

NEW HAVEN, Conn., June 5, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

NEW HAVEN, Conn., June 3, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral ...

Trevi's Haduvio met its primary endpoint in a Phase 2b trial for IPF-related chronic cough, with statistically significant ...

(RTTNews) - Trevi Therapeutics, Inc. (TRVI), a clinical-stage biopharmaceutical company focused on developing Haduvio - oral nalbuphine ER for chronic cough in idiopathic pulmonary fibrosis - IPF ...

President and CEO of Trevi Therapeutics. "Chronic cough is one of the most debilitating comorbidities for patients with IPF, impacting an estimated 85% of these patients. There are no approved ...

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...